Literature DB >> 22407801

Nonclinical vaccine safety evaluation: advantages of continuous temperature monitoring using abdominally implanted data loggers.

Patricia Kaaijk1, Arno A J van der Ark, Geert van Amerongen, Germie P J M van den Dobbelsteen.   

Abstract

Fever has been reported as the most common adverse event after vaccination in infants and children. For this reason it is important that, prior to clinical testing of a new vaccine, change in body temperature following vaccination is tested carefully in nonclinical animal studies. Since both the timing and the height of the temperature peak after vaccination may differ from vaccine to vaccine, it is important that the time point for body temperature measurement should be chosen on a case-by-case basis with sufficient knowledge of the specific vaccine. In order to determine the best time point for rectal body temperature measurement after vaccination with a new vaccine candidate against N. meningitidis serogroup B, to be applied in a formal Good Laboratory Practice (GLP) toxicology study, miniature temperature data loggers were implanted into the peritoneal cavity of rabbits. The continuous body temperature monitoring appeared to give a complete picture of the entire body temperature kinetics after vaccination. The body temperature peaked at 4 h after vaccination, and this time point was subsequently applied in the toxicology study. Measured body temperature values at the selected time point of 4 h after vaccination were comparable in the continuous temperature setting and in the formal toxicology study, i.e. rectal temperature measurement at one time point. In the present study implanted temperature loggers were successfully used to define an adequate time point to be applied in determining rectal body temperature in a formal GLP toxicology study with a new vaccine candidate.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22407801     DOI: 10.1002/jat.2720

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  3 in total

1.  An improved whole cell pertussis vaccine with reduced content of endotoxin.

Authors:  Waldely Oliveira Dias; Arno A J van der Ark; Maria Aparecida Sakauchi; Flávia Saldanha Kubrusly; Ana Fabíola R O Prestes; Monamaris Marques Borges; Noemi Furuyama; Denise S P Q Horton; Wagner Quintilio; Marta Antoniazi; Betsy Kuipers; Bernard A M van der Zeijst; Isaias Raw
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

Review 2.  Outer membrane vesicles: moving within the intricate labyrinth of assays that can predict risks of reactogenicity in humans.

Authors:  Omar Rossi; Francesco Citiulo; Francesca Mancini
Journal:  Hum Vaccin Immunother       Date:  2020-07-20       Impact factor: 3.452

3.  An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.

Authors:  Peter A van der Ley; Afshin Zariri; Elly van Riet; Dinja Oosterhoff; Corine P Kruiswijk
Journal:  Front Immunol       Date:  2021-12-17       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.